Novartis Vaccines & Diagnostics, Gmbh

Shanghai Fochon Pharmaceutical Co., Ltd.

Fochon Pharmaceuticals, Ltd.

Chinese Academy of Sciences

Chongqing Fochon Pharmaceutical Co., Ltd.

Novartis Ag

Chiron Corporation

Fochon Pharma, Inc.

Fochon Biosciences, Ltd.

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Fochon Pharmaceutical Co., Ltd.

Weibo Wang

Xingdong Zhao

Haohan Tan

Xianlong Wang

Tongshuang Li

Zuwen Zhou

Yanxin Liu

Jing Sun

Rui Tan

Lihua Jiang

Zhifu Li

Zhifang Chen

Ling Chen

Liana Marie Lagniton

Ryan N Constantine

Qihong Liu

Weipeng Zhang

Hongbin Liu

Yue Rong

Savithri Ramurthy

Paul Andrew Barsanti

Qiang Tian

Hong Yang

Annette Olga Walter

Nathan Brammeier

Lijun Yang

Min Lin

Huajie Zhang

Sabina Pecchi

Sharadha Subramanian

Kris Mendenhall

Elizabeth J Mieuli

Anu Sharma

Rustum Boyce

Megan C Phillips

Chengxi He

Paul A Renhowe

Keith Bruce Pfister

Allan S Wagman

Yi Xia

Simon C Ng

David Duhl

Kenneth Walter Bair

Tinya Abrams

Eric J Martin

Rama Jain

Kelly Wayman

Zongyao Zou

Bin Liu

Li Linghu

Fanxin Zeng

Jian Ding

Mark Knapp

Meiyu Geng

Elisa Jazan

Vincent P Le

Kay Huh

Shu Lin

Kai Ran

Manoj C Desai

Martin Sendzik

James Clifford Sutton

Jiong Lan

Matthew T Burger

Hongyan Guo

Mika Lindvall

Zhi-Jie Ni

Rustum S Boyce

Jing Ai

Xia Peng

Marion Wiesmann

Victoria Sung

Jiemin Fu

Liana M Klivansky

William Lenahan

Susan Kaufman

Chuiliang Yu

Yia Xia

Yunling Wang

Yuwei Gao

Quan Yuan

Hailong Shi

Bo Fang

Yasheen Zhou

Xiaodong Lin

Amy J Weiner

Nicholas M Valiante

Alice C Rico

Payman Amiri

Robert L Warne

Linghua Meng

Mina E Aikawa

Jeffrey H Dove

Johanna M Jansen

Wei Shu

Eliza Jazan

Tao Cheng

Liana Marie Lagnition

Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Apoptosis-inducing agents

Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Macrocyclic compounds as TRK kinases inhibitors

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds thereof, and use of these compounds in preparing drugs for inhibiting ROCK. 

Deuterated compounds as rock inhibitors

Provided are certain TRK inhibitors of formula (I): pharmaceutical compositions thereof, and methods of use thereof.

Substituted 2-azabicyclo[3.1.0]hexanes as TRK kinases inhibitors

Provided are certain IDO inhibitors or pharmaceutically acceptable salts thereof which can inhibit enzymatic activity of indoleamine 2,3-dioxygenase (IDO) and may be useful for the treatment of diseases and disorders mediated by IDO. In addition, pharmaceutical compositions thereof and methods of use thereof are also provided.

Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase

Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bcl-2 inhibitors can be used to treat cell proliferative disorders. 

Compounds as BLC-2-selective apoptosis-inducing agents

Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Indolizine derivatives, composition and methods of use

Certain CDK4/6 inhibitors and pharmaceutically acceptable salts thereof are described. In particular, these compounds can inhibit kinase activity of CDK4/6 and may be useful for the treatment of hyper-proliferative diseases like cancer and inflammation. In addition, the pharmaceutical compositions thereof and methods of use thereof are also described.

Certain protein kinase inhibitors

Provided are certain compounds or pharmaceutically acceptable salts thereof which can inhibit kinase activity of Bruton's tyrosine kinase (BTK) and may be useful for the treatment of diseases like cancer, immunological disease and inflammation.

Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors

Provided are certain CDK4/6 inhibitors with the structure of formula (I), pharmaceutical compositions thereof, and methods of use therefor. The compounds are of the class of pyrimidin-2 amine derivatives, useful for the treatment of hyper-proliferative diseases. 

Certain protein kinase inhibitor

Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Provided are compound of formula (I) as certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof. 

Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof, and method of use thereof.

Quinazoline derivatives, compositions thereof, and use as pharmaceuticals

Disclosed herein are protein kinase inhibitors, more particularly pyridazine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Growing community of inventors

Moraga, CA, United States of America

Weibo Wang